Author

Ben Z. Stanger

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract IA007: Getting ahead of the tumor: Interception approaches for pancreas cancer

Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...

Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al. · Cancer Research · 0 citations

Sep 2026

Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing

Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...

Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al. · Cancer Research · 0 citations

Open access Aug 2026

The CA19-9 glycan is a viable target for CAR T cell therapy in pancreatic and other solid tumors.

BACKGROUND & AIMS Chimeric antigen receptor (CAR) T cell therapy for pancreatic ductal adenocarcinoma (PDAC) has been challenging, in part due to the paucity of tumor-specific cell-surface targets. Here, we explored the design feasibility and anti-tumor efficacy of CAR T cells recognizing the CA19-9 glycan, a tumor ant...

Fei-Yan Mo, Austin L. Good, Jayne C. McDevitt et al. · Gastroenterology · 0 citations